Phase 1/2CompletedAge-related condition
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A PhaseⅠ/Ⅱa, Randomized and Double-blinded Clinical Trial
- Sponsor
- Shanghai AbelZeta Ltd. (Industry)
- Enrolment
- 18 enrolled
- Conditions
- Knee Osteoarthritis
- Interventions
- Mesenchymal stem cells low-dose group; Mesenchymal stem cells mid-dose group; Mesenchymal stem cells high-dose group
- Ages
- adults, older adults
- Registry
- NCT01809769
Full record on ClinicalTrials.gov
From the registry
Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.
Primary outcomes
- Recording of Adverse Events and Serious Adverse Events
- Electrocardiogram
- Vital signs
- Physical examination
History
Last registry update
Study completion
Primary completion
Started
Registered